Hemispherx Biopharma | HEB | Profile | Summary
Hemispherx Biopharma (HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®.
Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in New Brunswick, New Jersey.
ALFERON
Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection. Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.
Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.
ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.
Clinically Effective:
All warts disappeared in 54% of patients.3
No recurrence in 76% of complete responders at follow-up.3
Completely cleared 73% of all treated warts.3,4
No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
Provides a spectrum of multiple alpha interferon subtypes.1,
What's in the Pipeline?
Ampligen® (poly I:poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching. Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza.
Watch This!
On July 31, 2012 Hemispherx submitted its complete response to the FDA’s Complete Response Letter in support of Ampligen®’s New Drug Application for Chronic Fatigue Syndrome (“CFS”).
Its too early to tell what the FDA's response would be, however, the response from investors has been very positive. We alerted our members and followers last week and we believe this company should be on your radar!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
